TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
LQDA

Liquidia Technologies Inc

Healthcare · Drug Manufacturers - Specialty & Generic

78.80$ -10.5% vs. previous close Closing price · As of: Aug 12, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Liquidia Technologies Inc (LQDA). It shows which part of the business is growing — and which one is holding it back.

Revenue by business segment

Revenue by business segment — LQDA
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Single reportable segment EZQ3.1M 100.0% EZQ8.8M 100.0% EZQ132.9M 100.0% EZQ171.7M 100.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Operating income — LQDA
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Single reportable segment -EZQ35.4M -1,135.4% -EZQ37.5M -424.4% EZQ61.5M 46.3% EZQ85.5M 49.8%

Large figure: segment operating income. Below it the margin, that is operating income measured against the revenue of the same segment.

Revenue by product line

Revenue by product line — LQDA
Segment Q1 2025 Q2 2025 Q1 2026 Q2 2026
Product sales, net EZQ6.5M 73.7% EZQ129.9M 97.8% EZQ170.4M 99.2%
Service revenue, net EZQ3.1M 100.0% EZQ2.3M 26.3% EZQ3.0M 2.2% EZQ1.3M 0.8%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?